Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012349 | 0.97 | TSHR (0.40) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL2061168 | 0.97 | TSHR (0.40) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL21119348 | 0.97 | TSHR (0.40) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL15774512 | 0.95 | — | — | |
| SCHEMBL14152208 | 0.89 | — | — | |
| SCHEMBL21119408 | 0.82 | — | — | |
| SCHEMBL289131 | 0.79 | CYP1A2 (0.52) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL15774425 | 0.78 | KDM4E (0.39) | KDM4E | |
| SCHEMBL15774956 | 0.78 | — | — | |
| SCHEMBL15774458 | 0.78 | KDM4E (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | claimed |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | L'OREAL (FR) | 2022-08-02 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20190125051-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'OREAL (FR) | 2019-05-02 | — | — | US | disclosed |
| US-10092490-B2 | Method for straightening keratinous fibres using heating means and an amide | L'OREAL (FR) | 2018-10-09 | — | — | US | disclosed |
| US-20140326268-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'OREAL (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8765107-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | L'OREAL (FR) | 2014-07-01 | — | — | US | disclosed |
| US-20120192888-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L 'Oréal S.A., (FR) | 2012-08-02 | — | — | US | disclosed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-7008959-B2 | Form of irbesartan, processes for obtaining the said and pharmaceutical compositions containing it | SANOFI-AVENTIS (FR) | 2006-03-07 | — | — | US | disclosed |
| US-20050032862-A1 | Novel form of irbesartan, processes for obtaining the said and pharmaceutical compositions containing it | SANOFI (FR) | 2005-02-10 | — | — | US | disclosed |
| US-6800761-B1 | CRYSTALLINE FORM OF IRBESARTAN HAVING CRYSTAL HABIT SUCH THAT RATIO BETWEEN LENGTH AND WIDTH OF CRYSTALS IS BETWEEN 1:1 AND 10:1 | SANOFI-SYNTHELABO (FR) | 2004-10-05 | — | — | US | disclosed |
| EP-1089994-B1 | NOVEL FORM OF IRBESARTAN, METHODS FOR OBTAINING SAID FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
| EP-1089994-A1 | NOVEL FORM OF IRBESARTAN, METHODS FOR OBTAINING SAID FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067236-A1 | NOVEL FORM OF IRBESARTAN, METHODS FOR OBTAINING SAID FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 1999-12-29 | — | — | WO | disclosed |
| US-5559233-A | 3-/P-PHENYLBENZYL/IMIDAZOLONES AND PYRIMIDONES | SANOFI (FR) | 1996-09-24 | — | — | US | disclosed |
| US-5541209-A | Use of irbesartan or salts thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5352788-A | Angiotensin antagonist | ELF SANOFI (FR) | 1994-10-04 | — | — | US | disclosed |
| US-5270317-A | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120192888-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | KRT18, KRTCAP2, TUBB4A | TSHR 4635/4885USP2 1836/4885ALDH1A1 2916/4885 |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | KRT18, KRTCAP2, TUBB4A | TSHR 4635/4885USP2 1836/4885ALDH1A1 2916/4885 |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | TSHR 1454/4885USP2 3173/4885ALDH1A1 271/4885 |
| US-20190125051-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | KRT18, KRTCAP2, TUBB4A | TSHR 4635/4885USP2 1836/4885ALDH1A1 2916/4885 |
| US-11091465-B2 | — | HTRA1, ALDH1A2, ADCYAP1R1 | TSHR 1559/4885USP2 3685/4885ALDH1A1 207/4885 |
| US-20050032862-A1 | Novel form of irbesartan, processes for obtaining the said and pharmaceutical compositions containing it | REN, AGTR1, AGTR2 | TSHR 1990/4885USP2 2927/4885ALDH1A1 3450/4885 |
| US-10092490-B2 | Method for straightening keratinous fibres using heating means and an amide | KRT18, TUBB3, KIF5C | TSHR 4076/4885USP2 2961/4885ALDH1A1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.